The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. In June 2021, Novo Nordisk won ...

Researchers analysed data from two million US veterans with type 2 diabetes who used Ozempic, Wegovy, or standard treatments.

A new study published in the Nature Medicine monthly journal highlights the benefits and risks of weight-loss drugs like ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Researchers have found links to multiple new benefits – and new side effects – in a study of weight-loss drugs such as ...

A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.